Cisatracurium



Cisatracurium
Systematic (IUPAC) name
5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-
dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]
propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxy
phenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-
1H-isoquinolin-2-yl]propanoate
Identifiers
CAS number 96946-42-8
ATC code M03AC11
PubChem 62887
DrugBank APRD00874
Chemical data
O12+2
Mol. mass 929.145 g/mol
Pharmacokinetic data
Bioavailability N/A - IV use only
Protein binding Unknown due to rapid degradation
Metabolism 80% Hoffman elmination/ Hepatic
Half life 20-29 minutes
Excretion 10-15% unchanged
Therapeutic considerations
Pregnancy cat.

B

Legal status
Routes IV only

Cisatracurium (usually as cisatracurium besilate, trade name Nimbex) is a metabolites contain less laudanosine which cause hypotension, central nervous system excitement, and seizures than that of atracurium. It is considered an intermediate-acting agent in terms of duration of action.

Structure

It is a benzyl-isoquinolinium agent in the quaternary ammonium compound family.

Metabolism

80% is metabolized to laudanosine via Hoffman Elimination (which is dependent on the pH and the temperature of the plasma) and 20% is metabolized hepatically or excreted renally. Since Hoffman elimination is organ-independent, the use of cisatracurium may pose less risk in patients with liver or renal disease than other neuromuscular blockers. 10-15% of the dose is excreted unchanged in the urine.

v • d • e
Dantrolene
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cisatracurium". A list of authors is available in Wikipedia.